Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Janux Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Developing Tumor-Activated Immunotherapies For Cancer. The Proprietary Technology Of The Company Has Enabled The Development Of Distinct Bispecific Platforms: Tumor Activated T Cell Engagers (Tractr), Tumor Activated Immunomodulators (Tracir), And Adaptive Immune Response Modulator (Arm) Platforms. The Tractr Platform Produces T Cell Engagers (Tces) With A Tumor Antigen-Binding Domain And A Cd3 T Cell Binding Domain, While The Tracir Platform Produces Bispecifics With A Tumor Antigen-Binding Domain And A Costimulatory Cd28 Binding Domain.